Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Identification and management of familial hypercholesterolaemia

Tools
- Tools
+ Tools

DeMott, K., Nherera, L., Humphries, S. E., Minhas, R., Shaw, E. J., Kathoria, M., Ritchie, G., Davies, D., Lee, P., McDowell, I., Neil, A., Qureshi, N., Rowlands, P., Seed, M., Stracey, H., Thorogood, Margaret and Watson, M. (2008) Identification and management of familial hypercholesterolaemia. London: National Institute for Health and Clinical Excellence (NICE). (NICE clinical guideline).

Research output not available from this repository, contact author.
Official URL: http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuid...

Request Changes to record.

Abstract

In some people, a high cholesterol concentration in the blood is caused by an inherited genetic defect known as familial hypercholesterolaemia (FH). A raised cholesterol concentration in the blood is present from birth and may
lead to early development of atherosclerosis and coronary heart disease. The disease shows an autosomal dominant pattern of inheritance, being transmitted from generation to generation in such a way that siblings and
children of a person with FH have a 50% risk of inheriting FH. Most people with FH have inherited a defective gene for FH from only one parent and are therefore heterozygous. Rarely, a person will inherit a genetic
defect from both parents and will have homozygous FH or compound heterozygous FH, which will be collectively termed homozygous FH for the purpose of this guideline.
The prevalence of heterozygous FH in the UK population is estimated to be 1 in 500, which means that approximately 110,000 people are affected. The elevated serum cholesterol concentration that characterises heterozygous FH leads to a greater than 50% risk of coronary heart disease in men by the age of 50 years and at least 30% in women by the age of 60 years.
Homozygous FH is rare, with symptoms appearing in childhood, and is associated with early death from coronary heart disease. Homozygous FH has an incidence of approximately one case per one million. The guideline will assume that prescribers will use a drug’s summary of
product characteristics to inform their decisions for individual patients.

Item Type: Report
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Series Name: NICE clinical guideline
Publisher: National Institute for Health and Clinical Excellence (NICE)
Place of Publication: London
Official Date: August 2008
Dates:
DateEvent
August 2008Published
Number: No.71
Number of Pages: 45
Status: Not Peer Reviewed
Publication Status: Published
Description:

NICE clinical guideline 71

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us